MA51312A - Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb) - Google Patents

Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)

Info

Publication number
MA51312A
MA51312A MA051312A MA51312A MA51312A MA 51312 A MA51312 A MA 51312A MA 051312 A MA051312 A MA 051312A MA 51312 A MA51312 A MA 51312A MA 51312 A MA51312 A MA 51312A
Authority
MA
Morocco
Prior art keywords
hbv
hepatitis
virus
inducing
compositions
Prior art date
Application number
MA051312A
Other languages
English (en)
Inventor
Daniel Boden
Jerome Hubertina Henricus Victor Custers
Pooter Dorien De
Helen Horton
Markus Kalla
Jean-Marc Edmond Fernand Marie Neefs
Soumitra Roy
Roland Christian Zahn
Original Assignee
Bavarian Nordic As
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As, Janssen Sciences Ireland Unlimited Co filed Critical Bavarian Nordic As
Publication of MA51312A publication Critical patent/MA51312A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA051312A 2017-12-19 2018-12-18 Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb) MA51312A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607439P 2017-12-19 2017-12-19
IB2017058148 2017-12-19

Publications (1)

Publication Number Publication Date
MA51312A true MA51312A (fr) 2020-10-28

Family

ID=65201641

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051312A MA51312A (fr) 2017-12-19 2018-12-18 Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)

Country Status (12)

Country Link
EP (1) EP3727446A1 (fr)
JP (1) JP2021506300A (fr)
KR (1) KR20200100745A (fr)
CN (1) CN111741766A (fr)
AU (1) AU2018389786A1 (fr)
BR (1) BR112020012273A2 (fr)
CA (1) CA3086325A1 (fr)
IL (1) IL275423A (fr)
MA (1) MA51312A (fr)
MX (1) MX2020006471A (fr)
SG (1) SG11202005710YA (fr)
WO (1) WO2019123250A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
WO2020255055A1 (fr) * 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (fr) 1904-11-07 1905-03-14 William Waid Paddock Filtre a pression
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
JP2001520537A (ja) 1997-04-03 2001-10-30 エレクトロフェクト・アクティーゼルスカブ 医薬品と核酸の骨格筋への導入方法
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
KR20010020571A (ko) 1997-06-30 2001-03-15 자끄 사비나 횡문근중으로 개선된 핵산 전달방법 및 이를 위한콤비네이션
JP2003505114A (ja) 1998-07-13 2003-02-12 ジェネトロニクス、インコーポレーテッド パルス電場による皮膚および筋肉を標的とした遺伝子治療
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
DE60043126D1 (de) 1999-05-17 2009-11-19 Crucell Holland Bv Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1598425A1 (fr) 2000-11-23 2005-11-23 Bavarian Nordic A/S Variant modifié du virus de la vaccine ankara
CN101397574A (zh) 2001-12-04 2009-04-01 巴法里安诺迪克有限公司 黄病毒ns1亚单位疫苗
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7285265B2 (en) 2002-04-25 2007-10-23 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
PL215165B1 (pl) 2002-04-25 2013-10-31 Crucell Holland Bv Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
AU2005221687A1 (en) 2004-03-08 2005-09-22 Ichor Medical Systems, Inc. Improved apparatus for electrically mediated delivery of therapeutic agents
CN101248173A (zh) * 2005-04-08 2008-08-20 墨尔本保健公司 对于抗病毒核苷试剂具有抗性的乙型肝炎病毒变异体及其应用
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
CA2666501C (fr) 2006-10-17 2017-03-21 Vgx Pharmaceuticals, Inc. Dispositifs d'electroporation et leurs procedes d'utilisation pour l'electroporation de cellules de mammiferes
WO2009056535A2 (fr) * 2007-10-29 2009-05-07 Genimmune N.V. Procédés et kits permettant d'induire une réponse de ltc en utilisant un schéma de primovaccination/rappel
NZ592082A (en) 2008-11-27 2013-03-28 Bavarian Nordic As Promoters for recombinant viral expression
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
AU2010209938A1 (en) 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
CA2770075C (fr) * 2009-08-07 2021-08-24 Perrine Martin Composition pour le traitement d'une infection par le virus de l'hepatite b
AU2011343798B2 (en) 2010-12-14 2016-07-14 Janssen Vaccines & Prevention B.V. Adenovirus serotype 26 and serotype 35 filovirus vaccines
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
SG10201704657WA (en) 2012-10-28 2017-07-28 Bavarian Nordic As Pr13.5 promoter for robust t-cell and antibody responses
KR102565284B1 (ko) 2015-07-31 2023-08-08 버베리안 노딕 에이/에스 폭스바이러스에서 발현을 증강하기 위한 프로모터
DK3402888T3 (da) * 2016-01-12 2020-11-30 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Middel og fremgangsmåder til behandling af hbv
KR102535764B1 (ko) 2016-03-28 2023-05-30 아이커 메디칼 시스템스 인코포레이티드 치료제를 전달하기 위한 장치

Also Published As

Publication number Publication date
WO2019123250A1 (fr) 2019-06-27
IL275423A (en) 2020-08-31
CA3086325A1 (fr) 2019-06-27
SG11202005710YA (en) 2020-07-29
BR112020012273A2 (pt) 2020-11-24
MX2020006471A (es) 2020-09-22
AU2018389786A1 (en) 2020-06-18
CN111741766A (zh) 2020-10-02
EP3727446A1 (fr) 2020-10-28
JP2021506300A (ja) 2021-02-22
KR20200100745A (ko) 2020-08-26

Similar Documents

Publication Publication Date Title
ZA201906252B (en) Hepatitis b virus surface antigen inhibitor
MA51312A (fr) Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
IL258697A (en) Methods related to crispr/cas and compositions for the treatment of viral hepatitis b
MA50520A (fr) Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
HK1255502A1 (zh) B型肝炎病毒(hbv)irna組合物及其使用方法
MA45863A (fr) Agent arni contre l'infection par le virus de l'hépatite b
HK1255847A1 (zh) 針對乙型肝炎病毒的疫苗
MA52701A (fr) Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b
IL274298A (en) Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv)
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
HK1248278A1 (zh) 用於使乙型肝炎病毒基因表達沉默的組合物及方法
EP3426633A4 (fr) Élimination du virus de l'hépatite b par des agents antiviraux
IL265921A (en) Transgenic meganonucleases specific for recognition sequences in the hepatitis b virus genome
MA51292A (fr) Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb)
EP3632914A4 (fr) Inhibiteur d'antigène de surface du virus de l'hépatite b
IL290924A (en) Vaccines for hepatitis b virus
EP3541960A4 (fr) Procédés et dispositifs pour la détection du virus de l'hépatite c
HK1259329A1 (zh) 包含乙型肝炎病毒的表面抗原和核衣殼抗原的藥用組合物
EP3473639A4 (fr) Inhibiteur du virus de l'hépatite c et application
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
EP3445367A4 (fr) Inhibiteurs du virus de l'hépatite c
PL3244921T3 (pl) Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV